Cargando…
Crude extract and isolated bioactive compounds from Notholirion thomsonianum (Royale) Stapf as multitargets antidiabetic agents: in-vitro and molecular docking approaches
BACKGROUND: Diabetes mellitus is a common disease effecting the lifestyles of majority world population. In this research work, we have embarked the potential role of crude extracts and isolated compounds of Notholirion thomsonianum for the management diabetes mellitus. METHODS: The crude extracts o...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549260/ https://www.ncbi.nlm.nih.gov/pubmed/34706708 http://dx.doi.org/10.1186/s12906-021-03443-7 |
_version_ | 1784590747691909120 |
---|---|
author | Mahnashi, Mater H. Alqahtani, Yahya S. Alqarni, Ali O. Alyami, Bandar A. Jan, Muhammad Saeed Ayaz, Muhammad Ullah, Farhat Rashid, Umer Sadiq, Abdul |
author_facet | Mahnashi, Mater H. Alqahtani, Yahya S. Alqarni, Ali O. Alyami, Bandar A. Jan, Muhammad Saeed Ayaz, Muhammad Ullah, Farhat Rashid, Umer Sadiq, Abdul |
author_sort | Mahnashi, Mater H. |
collection | PubMed |
description | BACKGROUND: Diabetes mellitus is a common disease effecting the lifestyles of majority world population. In this research work, we have embarked the potential role of crude extracts and isolated compounds of Notholirion thomsonianum for the management diabetes mellitus. METHODS: The crude extracts of N. thomsonianum were initially evaluated for α-glucosidase, α-amylase and antioxidant activities. The compounds were isolated from the activity based potent solvent fraction. The structures of isolated compounds were confirmed with NMR and MS analyses. The isolated compounds were tested for α-glucosidase, α-amylase, protein tyrosine phosphatase 1B (PTP1B) and DPPH activities. The molecular docking studies were carried out to find the binding interactions of isolated compounds for α-glucosidase, α-amylase and PTP1B. RESULTS: Initially, we screened out crude extracts and subfractions of N. thomsonianum against different in-vitro targets. Among all, Nt.EtAc was observed a potent fraction among all giving IC(50) values of 67, 70, < 0.1, 89 and 16 μg/mL against α-glucosidase, α-amylase, DPPH, ABTS and H(2)O(2) respectively. Three compounds (Nt01, Nt02 and Nt03) were isolated from Nt.EtAc of N. thomsonianum. The isolated compounds Nt01, Nt02 and Nt03 exhibited IC(50) values of 58.93, 114.93 and 19.54 μM against α-glucosidase, while 56.25, 96.54 and 24.39 μM against α-amylase respectively. Comparatively, the standard acarbose observed IC(50) values were 10.60 and 12.71 μM against α-glucosidase, α-amylase respectively. In PTP1B assay, the compounds Nt01, Nt02 and Nt03 demonstrated IC(50) values of 12.96, 36.22 and 3.57 μM in comparison to the standard ursolic acid (IC(50) of 3.63 μM). The isolated compounds also gave overwhelming results in DPPH assay. Molecular docking based binding interactions for α-glucosidase, α-amylase and PTP1B were also encouraging. CONCLUSIONS: In the light of current results, it is obvious that N. thomsonianum is potential medicinal plant for the treatment of hyperglycemia. Overall, Nt.EtAc was dominant fraction in all in-vitro activities. Three compounds Nt01, Nt02 and Nt03 were isolated from ethyl acetate fraction. The Nt03 specifically was most potent in all in-vitro assays. The molecular docking studies supported our in-vitro results. It is concluded that N. thomsonianum is a rich source of bioactive antidiabetic compounds which can be further extended to in-vivo based experiments. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12906-021-03443-7. |
format | Online Article Text |
id | pubmed-8549260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85492602021-10-27 Crude extract and isolated bioactive compounds from Notholirion thomsonianum (Royale) Stapf as multitargets antidiabetic agents: in-vitro and molecular docking approaches Mahnashi, Mater H. Alqahtani, Yahya S. Alqarni, Ali O. Alyami, Bandar A. Jan, Muhammad Saeed Ayaz, Muhammad Ullah, Farhat Rashid, Umer Sadiq, Abdul BMC Complement Med Ther Research BACKGROUND: Diabetes mellitus is a common disease effecting the lifestyles of majority world population. In this research work, we have embarked the potential role of crude extracts and isolated compounds of Notholirion thomsonianum for the management diabetes mellitus. METHODS: The crude extracts of N. thomsonianum were initially evaluated for α-glucosidase, α-amylase and antioxidant activities. The compounds were isolated from the activity based potent solvent fraction. The structures of isolated compounds were confirmed with NMR and MS analyses. The isolated compounds were tested for α-glucosidase, α-amylase, protein tyrosine phosphatase 1B (PTP1B) and DPPH activities. The molecular docking studies were carried out to find the binding interactions of isolated compounds for α-glucosidase, α-amylase and PTP1B. RESULTS: Initially, we screened out crude extracts and subfractions of N. thomsonianum against different in-vitro targets. Among all, Nt.EtAc was observed a potent fraction among all giving IC(50) values of 67, 70, < 0.1, 89 and 16 μg/mL against α-glucosidase, α-amylase, DPPH, ABTS and H(2)O(2) respectively. Three compounds (Nt01, Nt02 and Nt03) were isolated from Nt.EtAc of N. thomsonianum. The isolated compounds Nt01, Nt02 and Nt03 exhibited IC(50) values of 58.93, 114.93 and 19.54 μM against α-glucosidase, while 56.25, 96.54 and 24.39 μM against α-amylase respectively. Comparatively, the standard acarbose observed IC(50) values were 10.60 and 12.71 μM against α-glucosidase, α-amylase respectively. In PTP1B assay, the compounds Nt01, Nt02 and Nt03 demonstrated IC(50) values of 12.96, 36.22 and 3.57 μM in comparison to the standard ursolic acid (IC(50) of 3.63 μM). The isolated compounds also gave overwhelming results in DPPH assay. Molecular docking based binding interactions for α-glucosidase, α-amylase and PTP1B were also encouraging. CONCLUSIONS: In the light of current results, it is obvious that N. thomsonianum is potential medicinal plant for the treatment of hyperglycemia. Overall, Nt.EtAc was dominant fraction in all in-vitro activities. Three compounds Nt01, Nt02 and Nt03 were isolated from ethyl acetate fraction. The Nt03 specifically was most potent in all in-vitro assays. The molecular docking studies supported our in-vitro results. It is concluded that N. thomsonianum is a rich source of bioactive antidiabetic compounds which can be further extended to in-vivo based experiments. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12906-021-03443-7. BioMed Central 2021-10-27 /pmc/articles/PMC8549260/ /pubmed/34706708 http://dx.doi.org/10.1186/s12906-021-03443-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Mahnashi, Mater H. Alqahtani, Yahya S. Alqarni, Ali O. Alyami, Bandar A. Jan, Muhammad Saeed Ayaz, Muhammad Ullah, Farhat Rashid, Umer Sadiq, Abdul Crude extract and isolated bioactive compounds from Notholirion thomsonianum (Royale) Stapf as multitargets antidiabetic agents: in-vitro and molecular docking approaches |
title | Crude extract and isolated bioactive compounds from Notholirion thomsonianum (Royale) Stapf as multitargets antidiabetic agents: in-vitro and molecular docking approaches |
title_full | Crude extract and isolated bioactive compounds from Notholirion thomsonianum (Royale) Stapf as multitargets antidiabetic agents: in-vitro and molecular docking approaches |
title_fullStr | Crude extract and isolated bioactive compounds from Notholirion thomsonianum (Royale) Stapf as multitargets antidiabetic agents: in-vitro and molecular docking approaches |
title_full_unstemmed | Crude extract and isolated bioactive compounds from Notholirion thomsonianum (Royale) Stapf as multitargets antidiabetic agents: in-vitro and molecular docking approaches |
title_short | Crude extract and isolated bioactive compounds from Notholirion thomsonianum (Royale) Stapf as multitargets antidiabetic agents: in-vitro and molecular docking approaches |
title_sort | crude extract and isolated bioactive compounds from notholirion thomsonianum (royale) stapf as multitargets antidiabetic agents: in-vitro and molecular docking approaches |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549260/ https://www.ncbi.nlm.nih.gov/pubmed/34706708 http://dx.doi.org/10.1186/s12906-021-03443-7 |
work_keys_str_mv | AT mahnashimaterh crudeextractandisolatedbioactivecompoundsfromnotholirionthomsonianumroyalestapfasmultitargetsantidiabeticagentsinvitroandmoleculardockingapproaches AT alqahtaniyahyas crudeextractandisolatedbioactivecompoundsfromnotholirionthomsonianumroyalestapfasmultitargetsantidiabeticagentsinvitroandmoleculardockingapproaches AT alqarnialio crudeextractandisolatedbioactivecompoundsfromnotholirionthomsonianumroyalestapfasmultitargetsantidiabeticagentsinvitroandmoleculardockingapproaches AT alyamibandara crudeextractandisolatedbioactivecompoundsfromnotholirionthomsonianumroyalestapfasmultitargetsantidiabeticagentsinvitroandmoleculardockingapproaches AT janmuhammadsaeed crudeextractandisolatedbioactivecompoundsfromnotholirionthomsonianumroyalestapfasmultitargetsantidiabeticagentsinvitroandmoleculardockingapproaches AT ayazmuhammad crudeextractandisolatedbioactivecompoundsfromnotholirionthomsonianumroyalestapfasmultitargetsantidiabeticagentsinvitroandmoleculardockingapproaches AT ullahfarhat crudeextractandisolatedbioactivecompoundsfromnotholirionthomsonianumroyalestapfasmultitargetsantidiabeticagentsinvitroandmoleculardockingapproaches AT rashidumer crudeextractandisolatedbioactivecompoundsfromnotholirionthomsonianumroyalestapfasmultitargetsantidiabeticagentsinvitroandmoleculardockingapproaches AT sadiqabdul crudeextractandisolatedbioactivecompoundsfromnotholirionthomsonianumroyalestapfasmultitargetsantidiabeticagentsinvitroandmoleculardockingapproaches |